ArticleWorld journal of gastroenterology2013
Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma.
Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Causal pathways of plasma metabolites: unveiling metabolic associations in liver diseases.Nutrition & metabolism · 2025Article
- Microbiota and metabolite alterations in pancreatic head and body/tail cancer patients.Cancer science · 2024Article
- Multiomics characterization of fatty acid metabolism for the clinical management of hepatocellular carcinoma.Scientific reports · 2023Article
- Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.Journal of proteome research · 2019Article
- Liver function and energy metabolism in hepatocellular carcinoma developed in patients with hepatitis B-related cirrhosis.Medicine · 2019Observational
- Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma.Metabolites · 2019Review
- Serum-based metabolic alterations in patients with papillary thyroid carcinoma unveiled by non-targeted 1H-NMR metabolomics approach.Iranian journal of basic medical sciences · 2018Article
- Model-driven discovery of long-chain fatty acid metabolic reprogramming in heterogeneous prostate cancer cells.PLoS computational biology · 2018Article
- Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation.Cancer management and research · 2018Review
- Robust Regression Analysis of GCMS Data Reveals Differential Rewiring of Metabolic Networks in Hepatitis B and C Patients.Metabolites · 2017Article
- Nuclear Magnetic Resonance technique in tumor metabolism.Genes & diseases · 2017Review
- Metabolic profiling of hepatitis B virus-related hepatocellular carcinoma with diverse differentiation grades.Oncology letters · 2017Article
- Metabonomics Research Progress on Liver Diseases.Canadian journal of gastroenterology & hepatology · 2017Review
- Serum Metabonomics of Mild Acute Pancreatitis.Journal of clinical laboratory analysis · 2016Article
- Plasma Metabolic Profile Determination in Young ST-segment Elevation Myocardial Infarction Patients with Ischemia and Reperfusion: Ultra-performance Liquid Chromatography and Mass Spectrometry for Pathway Analysis.Chinese medical journal · 2016Article
- Metabonomic window into hepatitis B virus-related hepatic diseases.World journal of hepatology · 2016Review
- Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort.BMC medicine · 2015Article
- Metabolomics for biomarker discovery in gastroenterological cancer.Metabolites · 2014Article
- Macro- and micro-environmental factors in clinical hepatocellular cancer.Seminars in oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo select characteristic endogenous metabolites in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients and to identify their molecular mechanism and potential clinical value.
methodsAn ultra performance liquid chromatography and linear trap quadrupole-Orbitrap XL-mass spectrometry platform was used to analyze endogenous metabolites in the homogenate of central tumor tissue, adjacent tissue and distant tissue obtained from 10 HBV-related HCC patients. After pretreatment with Mzmine software, including peak detection, alignment and normalization, the acquired data were treated with Simca-P+software to establish multivariate statistical analysis based on a pattern recognition technique and characteristic metabolites highly correlated with changing trends in metabolic profiling were selected and further identified.
resultsBased on data acquired using Mzmine software, a principal component analysis model (R2X = 66.9%, Q2 = 21.7%) with 6 principal components and an orthogonal partial least squares discriminant analysis model (R2X = 76.5%, R2Y = 93.7%, Q2 = 68.7%) with 2 predicted principal components and 5 orthogonal principal components were established in the three tissue groups. Forty-nine ions were selected, 33 ions passed the 2 related samples nonparametric test (P < 0.05) and 14 of these were further identified as characteristic metabolites that showed significant differences in levels between the central tumor tissue group and distant tumor tissue group, including 9 metabolites (L-phenylalanine, glycerophosphocholine, lysophosphatidylcholines, lysophosphatidylethanolamines and chenodeoxycholic acid glycine conjugate) which had been reported as serum metabolite biomarkers for HCC diagnosis in previous research, and 5 metabolites (beta-sitosterol, quinaldic acid, arachidyl carnitine, tetradecanal, and oleamide) which had not been reported before.
conclusionCharacteristic metabolites and metabolic pathways highly related to HCC pathogenesis and progression are identified through metabolic profiling analysis of HCC tissue homogenates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.